1.67  0 (0%)		04-10 16:00
Open: 1.67 High: 1.7529 Volume: 18,904		Pre. Close: 1.67 Low: 1.61 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	2.26	1-year :	2.61
Resists	First :	1.93	Second :	2.23
Pivot price	1.61
Supports	First :	1.45	Second :	1.2
MAs	MA(5) :	1.67	MA(20) :	1.7
	MA(100) :	1.88	MA(250) :	3.18
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	41	D(3) :	36.4
RSI	RSI(14): 48.6
52-week	High :	5.88	Low :	1.35

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CMMB ] has closed below upper band by 33.7%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.75 - 1.76	1.76 - 1.77
Low:	1.59 - 1.6	1.6 - 1.61
Close:	1.66 - 1.67	1.67 - 1.68

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Fri, 10 Apr 2026
Chemomab (CMMB) director discloses option-heavy initial share ownership - Stock Titan

Fri, 10 Apr 2026
Chemomab Therapeutics (CMMB) director discloses ADS holdings and vested options - Stock Titan

Fri, 10 Apr 2026
Chemomab (CMMB) CFO details ADS, option and RSU holdings in Form 3 - Stock Titan

Fri, 10 Apr 2026
Chemomab (CMMB) CDO John Lawler details option and RSU holdings - Stock Titan

Sat, 04 Apr 2026
CMMB PE Ratio & Valuation, Is CMMB Overvalued - Intellectia AI

Sat, 04 Apr 2026
CMMB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	509 (M)
Held by Insiders	11.5 (%)
Held by Institutions	9 (%)
Shares Short	41 (K)
Shares Short P.Month	21 (K)

EPS	-1.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.72
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-38.9 %
Return on Equity (ttm)	-69.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.32
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-1.16
PEG Ratio	0
Price to Book value	0.97
Price to Sales	0
Price to Cash Flow	-1.09

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.